Ardian agreed to acquire a majority stake in Neopharmed Gentili, an Italian drugmaker, from Mediolanum Farmaceutici, a pharmaceutical company. Financial terms were not disclosed. “We are proud that the Del Bono family has chosen Ardian as their partner for the development of Neopharmed Gentili, which represents an example of Italian entrepreneurial excellence combined with strong growth opportunities. Today Neopharmed Gentili is well-known within the Italian pharmaceutical industry and is ready to begin expanding internationally, through important partnerships with global players such as Merck and Teva Pharmaceutical. We are pleased to support the Del Bono family in this new challenge and we will do it with passion, thanks to the experience and skills that distinguish Ardian and the many development projects already followed in Italy together with entrepreneurs and managers at the head of family businesses,” Nicolò Saidelli, Ardian Managing Director and Head in Italy.